Nuo Therapeutics Inc
OTC:AURX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Nuo Therapeutics Inc
OTC:AURX
|
75.8m USD |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
31.9B USD |
Loading...
|
|
| US |
|
Ionis Pharmaceuticals Inc
NASDAQ:IONS
|
13.9B USD |
Loading...
|
|
| IE |
|
ICON PLC
NASDAQ:ICLR
|
11.6B USD |
Loading...
|
|
| US |
|
Gartner Inc
NYSE:IT
|
11.4B USD |
Loading...
|
|
| US |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
9.5B USD |
Loading...
|
|
| US |
|
Charles River Laboratories International Inc
NYSE:CRL
|
9.4B USD |
Loading...
|
|
| US |
|
Cytokinetics Inc
NASDAQ:CYTK
|
7.6B USD |
Loading...
|
|
| UK |
|
Verona Pharma PLC
NASDAQ:VRNA
|
7.4B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Nuo Therapeutics Inc
Glance View
Nuo Therapeutics, Inc. is a biomedical company. The company is headquartered in Houston, Texas and currently employs 7 full-time employees. The company went IPO on 2017-01-19. The firm's Aurix System is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds. The firm commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company’s Aurix point of care technology for the safe and efficient separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. The firm is marketing its products primarily within the United States. Nuo Therapeutics' s Aurix System produces a platelet rich plasma (PRP), gel at the point of care using the patient’s own platelets and plasma. The Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Nuo Therapeutics Inc is 70.4%, which is below its 3-year median of 78.4%.
Over the last 3 years, Nuo Therapeutics Inc’s Gross Margin has decreased from 75% to 70.4%. During this period, it reached a low of 70.4% on Sep 30, 2025 and a high of 82.8% on Jun 30, 2023.
